Three-dimensional (3D) printing has transformed the development of microneedle arrays (MNAs) by enabling exceptional control over their geometry, distribution, materials, and functionality in a single-step, customizable process. This review represents a design-centric framework that organizes recent advancements in four interconnected levers: (i) individual microneedle (MN) geometry and size; (ii) patch-level MN distribution and multi-array architectures; (iii) computer-aided design (CAD), finite element analysis (FEA), computational fluid dynamics (CFD), and artificial intelligence/machine learning (AI/ML)-driven optimization; and (iv) manufacturing constraints and emerging solutions for scalability and reproducibility. Outcomes show that small changes in the radius of the MN’s tip, the MN’s aspect ratio, the MN’s internal lattice architecture, and the spacing of the array can dramatically influence their insertion force, mechanical reliability, payload capacity, and therapeutic coverage. Now, digital tools can bridge the design and experimental outcomes, while novel morphologies, hybrid materials, and theranostic integrations are expanding the clinical potential of MNs. The remaining challenges, resolution-versus-throughput trade-offs, biocompatibility, batch-to-batch consistency, and lack of testing standardization are examined alongside promising directions in high-throughput 3D printing, stimuli-responsive materials, and closed-loop systems. Finally, rational, model-guided design strategies are positioning 3D-printed MNAs as versatile platforms for painless, patient-specific drug delivery, diagnostics, and personalized medicine.
Razzaghi et al. (Mon,) studied this question.